Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer.
Cancer
; 129(5): 740-749, 2023 03 01.
Article
in En
| MEDLINE
| ID: mdl-36517940
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
Limits:
Female
/
Humans
Language:
En
Journal:
Cancer
Year:
2023
Type:
Article
Affiliation country:
United States